[  概要   |   プレカンファレンス   |   1日目   |   2日目   |   3日目   ]

Tuesday, March 25

7:00am Registration (Open until 5:30pm)

8:00 Plenary Keynote Introduction
Harry Glorikian, Managing Partner, Scientia Advisors

8:15 Diagnosing the Disease: Disruptive Innovation in Healthcare
Clayton M. Christensen, DBA, Robert and Jane Cizik Professor of Business Administration, Harvard Business School

9:45 Coffee Break

10:15am ・1:15pm Morning Pre-Conference Short Courses*

Recommended Morning Short Courses*

(SC2) THE CHALLENGE OF THE BLOOD-BRAIN BARRIER ・A MEDICINAL CHEMISTRY PERSPECTIVE The In's and Out's of Blood-brain Transport: Blood-brain Barrier Physiology and Transport Methodologies Claude Dagenais, B.Pharm., Ph.D. Senior Scientist, Neuroscience Department, Amgen Inc. The Challenge of the Blood-brain Barrier Douglas K. Spracklin, Ph.D., Director, Biotransformation & Enzymology, Pfizer Inc.  Application of Pharmacokinetic/Pharmacodynamic Modeling to Centrally Targeted Agents Ellen Q. Wang, Ph.D., Senior Principal Scientist, Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development  Blood-brain Barrier Models Romeo Cecchelli, Ph.D., Vice President, University of Artois; Head, BBB Laboratory; Scientific Advisor, Cellial Technologies (SC3) ADMET CASE STUDIES FROM A MEDICINAL CHEMISTRY PERSPECTIVE In Vitro ADME Assays: Strategic Application to Drug Discovery Dhiren R. Thakker, Ph.D., Ferguson Distinguished Professor and Associate Dean, Research and Graduate Education, School of Pharmacy, UNC-Chapel Hill Solubility, Data Integration, in Vitro/in Vivo Correlations Philip S. Burton, Ph.D., Chief Executive & Scientific Officer, ADMETRx, Inc. In Vitro Toxicity Assays That Have in Vivo Relevance James McKim, Ph.D., DABT, President & Chief Scientific Officer, CeeTox, Inc. Case Study: Impact of Structure and Physchem Properties on Oral Delivery of Antivirals Gail L Strong, Ph.D., Director, Pharmaceutical Sciences, Theravance, Inc.  2:30 - 5:30 Afternoon Pre-Conference Short Course*

Recommended Afternoon Short Course*

(SC8) MODELS FOR EVALUATING DRUG-DRUG INTERACTION POTENTIAL IN PRECLINICAL DEVELOPMENT From Benchtop to Regulatory Guidance: Effective Strategies to Identify Drug-Drug Interaction (DDI) Liability  Joseph Ware, Ph.D., Senior Scientist, Late Stage PK/PD, Genentech, Inc. In Vitro Models of CYP Inhibition and Induction James McKim, Ph.D., DABT, President & Chief Scientific Officer, CeeTox, Inc. In Vitro Drug Transporter Models Philip S. Burton, Ph.D., Chief Executive & Scientific Officer, ADMETRx, Inc. * Separate Registration Required